Holen Sie sich die Stockscreener-App
25.62
1.50%
-0.39
Handel nachbörslich:
25.65
0.03
+0.12%
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Stoke Therapeutics stock sits 35.28 percent below its high as Bo Cumbo joins board - AD HOC NEWS
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - Kalkine Media
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan
Stoke Therapeutics stock reports USD 9.33 million Q2 revenue - AD HOC NEWS
Ruth Walker Appointed Vice President, People & Culture at Stoke Therapeutics - hrtoday.in
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com India
[Form 3] Stoke Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan
Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media
(STOK) Risk Channels and Responsive Allocation - Stock Traders Daily
Stoke Therapeutics, Inc. (STOK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, E - The National Law Review
Stoke Therapeutics appoints Bo Cumbo to board of directors By Investing.com - Investing.com Canada
STOK Looks 163.2% Overvalued on GF Value™ - GuruFocus
Stoke Therapeutics appoints Bo Cumbo to board of directors - Investing.com
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization - Business Wire
Stoke Therapeutics (NASDAQ:STOK) Shares Down 9%What's Next? - MarketBeat
Stoke Therapeutics Appoints Bo Cumbo to Its B - Moomoo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
News - planetario.buenosaires.gob.ar
Stoke Therapeutics stock holds gains after recent data update - AD HOC NEWS
Stoke Therapeutics, Inc. (STOK) Investor Outlook: Exploring a 60.60% Potential Upside in Biotechnology - DirectorsTalk Interviews
ETFs Investing in Stoke Therapeutics, Inc. Stocks - TradingView
Stoke (STOK) Breaks Out with +4.23% Surge Past $30.54 2026-09-17Zero Lag EMA - siam.in
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)September 16, 2026 - BioSpace
Avoiding Lag: Real-Time Signals in (STOK) Movement - Stock Traders Daily
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics at Cantor conference: dravet data, cash runway - Investing.com
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - The Manila Times
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics grants inducement options to new CSO - scanx.trade
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics stock gains on Dravet data and Cantor conference plans - ad-hoc-news.de
BIIB News | BIOGEN INC (NASDAQ:BIIB) - ChartMill
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Yahoo Finance
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP - MarketBeat
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com - Investing.com Nigeria
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome - Investing.com
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):